Global Short-Acting Insulin Market 2026 evolving with diabetes management needs

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Short-Acting Insulin Market At The End Of The 2026–2030 Forecast Period?

The short-acting insulin market has experienced substantial growth in recent years. This market is projected to expand from $11.54 billion in 2025 to $12.14 billion in 2026, at a compound annual growth rate (CAGR) of 5.3%. Historically, this growth can be attributed to the high prevalence of diabetes, widespread adoption of insulin therapy, hospital-based diabetes management practices, the expansion of insulin access programs, and improved rates of diabetes diagnosis.

The short-acting insulin market is set for considerable expansion over the next few years. It is forecast to grow to $14.87 billion in 2030, achieving a compound annual growth rate (CAGR) of 5.2%. This projected growth during the forecast period is driven by factors such as the increasing occurrence of type 2 diabetes, a rise in insulin dependence, the expansion of home-based diabetes care, advancements in insulin delivery technologies, and a growing demand for fast-acting insulin. Key developments expected in the forecast period include an escalating demand for post-meal blood glucose regulation, the increasing utilization of rapid-acting insulin analogues, wider adoption of pre-filled insulin pens, the broadening of intensive insulin therapy approaches, and a stronger focus on precise glycemic management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21287&type=smp

Which Market Drivers Are Supporting The Expansion Of The Short-Acting Insulin Market?

The escalating incidence of type 1 diabetes is anticipated to propel the growth of the short-acting insulin market moving forward. Type 1 diabetes, an autoimmune disorder, involves the body’s destruction of insulin-producing cells, thereby necessitating lifelong insulin therapy. The increasing prevalence of Type 1 diabetes stems from genetic factors, environmental triggers, and a rise in autoimmune disorders. Short-acting insulin effectively manages type 1 diabetes by delivering rapid blood sugar control and mirroring the natural insulin response. For example, in December 2023, data from Diabetes Australia, an Australia-based organization focused on raising awareness about diabetes, indicated that roughly 134,000 Australians were living with Type 1 diabetes in 2022, a figure that climbed to 135,423 by 2023. This clearly demonstrates how the increasing prevalence of type 1 diabetes is driving the expansion of the short-acting insulin market.

What Segment Types Make Up The Short-Acting Insulin Market?

The short-acting insulin market covered in this report is segmented –

1) By Formulation: Regular Insulin, Rapid-Acting Insulin

2) By Dosage Form: Vials, Pre-filled Pens, Cartridges

3) By Route Of Administration: Subcutaneous, Intravenous

4) By Patient Type: Type 1 Diabetes, Type 2 Diabetes

5) By Distribution Channel: Pharmacies, Hospital Pharmacies, Online Pharmacies

Subsegments:

1) By Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, Other Regular Insulin

2) By Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, Insulin Glulisine

Which Market Trends Are Creating New Opportunities In The Short-Acting Insulin Market?

Leading companies in the short-acting insulin market are prioritizing innovative offerings, such as interchangeable rapid-acting insulin biologics, to improve glycemic management and offer flexible substitution possibilities for patients with diabetes. An interchangeable rapid-acting insulin biologic refers to an insulin formulation, biologically sourced, that quickly lowers blood glucose levels after meals and has regulatory approval to be swapped for another equivalent insulin product without needing a new prescription, thereby providing adaptability in diabetes care and sustaining consistent glycemic control. As an illustration, in July 2025, Biocon Biologics, a US-based biosimilars company with headquarters in both India and the U.S., secured FDA approval for Kirsty (insulin aspart xjhz), distinguishing it as the first and only interchangeable rapid-acting insulin aspart in the United States. Kirsty is a biosimilar to NovoLog (insulin aspart), with clinical and analytical data confirming no significant differences in its safety, effectiveness, purity, or potency. It is provided as a 100 units/mL solution in both a prefilled pen for single-patient subcutaneous use and a multi-dose vial suitable for both subcutaneous and intravenous administration, aimed at enhancing glycemic control in adults and children diagnosed with diabetes mellitus.

Who Are The Key Players Driving Competition In The Short-Acting Insulin Market?

Major companies operating in the short-acting insulin market are Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., Aspen Pharmacare Holdings Limited

Read the full short-acting insulin market report here:

https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report

How Is The Short-Acting Insulin Market Distributed Across Key Geographic Regions?

North America was the largest region in the short-acting insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short-acting insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Short-Acting Insulin Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21287&type=smp

Browse Through More Reports Similar to the Global Short-Acting Insulin Market 2026, By The Business Research Company

Insuman Market Report 2026

https://www.thebusinessresearchcompany.com/report/insuman-global-market-report

Instant Tea Premix Market Report 2026

https://www.thebusinessresearchcompany.com/report/instant-tea-premix-global-market-report

Technical Insulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/technical-insulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795